罗格列酮对代谢综合征患者冠状动脉介入治疗术后的影响

目的观察罗格列酮对代谢综合征患者冠状动脉介入治疗（PCI）术后再狭窄率及代谢指标的影响。方法随机分成对照组（按常规治疗）和罗格列酮组（常规治疗＋罗格列酮治疗）,在行PCI术前1d,罗格列酮组患者在原来用药的基础上予罗格列酮8mg,poqd,以后以4mgd治疗;对照组采用原来药物治疗,不加用罗格列酮。两组患者术后常规随访6个月。结果罗格列酮组升高了HDL-C,降低了TG、CRP,有统计学意义（P〈0.05）;有降低PCI术后支架内再狭窄率趋势;未增加不良心血管事件发生率。结论罗格列酮能改善代谢综合征患者的血糖、血脂代谢指标,并可减轻炎症反应,有益于减少PCI术后支架内再狭窄。

Effect of rosiglitazone on the patients with metabolic syndrome after coronary intervention influence

Objective Rosiglitazone on metabolic syndrome coronary intervention（ PCI） restenosis rate and metabolic indexes. Methods Randomly divided into control group（ according to conventional treatment） and rosiglitazone group（ conventional therapy ＋ rosiglitazone） ,preoperative PCI line 1 d,rosiglitazone patients on the basis of the original drug to rosiglitazone 8 mg,po qd,later to 4 mg/d treatment; the control group,the original medication,without rosiglitazone. Two groups of patients received postoperative routine follow-up 6 mo. Results Rosiglitazone group had increased HDL-C,lower TG,CRP,there was significant（ P 0. 05） ; have reduced in-stent restenosis after PCI rate trends; not increase the incidence of adverse cardiovascular events. Conclusion Rosiglitazone in patients with metabolic syndrome can improve blood glucose and lipid metabolism,and reduce the inflammatory response,also reduce in-stent restenosis after PCI.